首页> 美国卫生研究院文献>Cancer Medicine >Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma
【2h】

Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma

机译:趋化因子CXCL1可能作为肝细胞癌的潜在分子靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was to screen for changes in chemokine and chemokine‐related genes that are expressed in hepatocellular carcinoma (HCC) as potential markers of HCC progression. Total RNA was extracted from tumor and peritumor tissues from mice with HCC and analyzed using a PCR microarray comprising 98 genes. Changes in gene expression of threefold or more were screened and subsequently confirmed by immunohistochemical analyses and western blotting. Furthermore, whether chemokine knockdown by RNA interference (RNAi) could significantly suppress tumor growth in vivo was also evaluated. Finally, total serum samples were collected from HCC patients with HBV/cirrhosis (n = 16) or liver cirrhosis (n = 16) and from healthy controls (n = 16). The serum mRNA and protein expression levels of CXCL1 in primary liver cancer patients were detected by qRT‐PCR and western blot analysis, respectively. Several genes were up‐regulated in tumor tissues during the progression period, including CXCL1, CXCL2, CXCL3, and style="fixed-case">IL‐1β, while style="fixed-case">CXCR1 expression was down‐regulated. style="fixed-case">CBRH‐7919 cells carrying style="fixed-case">CXCL1 si style="fixed-case">RNA resulted in decreased tumor growth in nude mice. The differences in serum style="fixed-case">CXCL1 style="fixed-case">mRNA and protein levels among the style="fixed-case">HCC, style="fixed-case"> hepatic sclerosis (HS), and control groups were significant (P < 0.001). The style="fixed-case">mRNA and protein levels of style="fixed-case">CXCL1 in the style="fixed-case">HCC group were up‐regulated compared with the style="fixed-case">HS group or the control group (P < 0.001). Several chemokine genes were identified that might play important roles in the tumor microenvironment of style="fixed-case">HCC. These results provide new insights into human style="fixed-case">HCC and may ultimately facilitate early style="fixed-case">HCC diagnosis and lead to the discovery of innovative therapeutic approaches for style="fixed-case">HCC.
机译:这项研究的目的是筛选在肝细胞癌(HCC)中表达的趋化因子和趋化因子相关基因的变化,作为肝癌进展的潜在标志。从患有HCC的小鼠的肿瘤和癌旁组织中提取总RNA,并使用包含98个基因的PCR微阵列进行分析。筛选三倍或更多倍的基因表达变化,随后通过免疫组织化学分析和蛋白质印迹证实。此外,还评估了通过RNA干扰(RNAi)引起的趋化因子敲低是否可以显着抑制体内肿瘤的生长。最后,从患有HBV /肝硬化(n = 16)或肝硬化(n = 16)的HCC患者和健康对照(n = 16)中收集总血清样本。通过qRT-PCR和western blot分析分别检测原发性肝癌患者血清CXCL1的mRNA和蛋白表达水平。在进展过程中,肿瘤组织中的一些基因上调,包括CXCL1,CXCL2,CXCL3和 style =“ fixed-case”> IL -1β,而 style =“ fixed-case” > CXCR 1表达下调。 style =“ fixed-case”> CBRH ‐7919细胞携带 style =“ fixed-case”> CXCL 1 si style =“ fixed-case”> RNA 导致裸鼠的肿瘤生长降低。 style =“ fixed-case”>之间的血清 style =“ fixed-case”> CXCL 1 style =“ fixed-case”> mRNA 和蛋白质水平的差异HCC , style =“ fixed-case”>肝硬化(HS)和对照组均显着(P <0.001)。 style =“ fixed-case”> HCC style =“ fixed-case”> mRNA 和 style =“ fixed-case”> CXCL 1的蛋白质水平/ span>组与 style =“ fixed-case”> HS 组或对照组相比上调(P <0.001)。鉴定了几种趋化因子基因,它们可能在 style =“ fixed-case”> HCC 的肿瘤微环境中发挥重要作用。这些结果为人类 style =“ fixed-case”> HCC 提供了新的见解,并可能最终有助于早期 style =“ fixed-case”> HCC 的诊断,并导致发现创新 style =“ fixed-case”> HCC 的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号